FDA approved PFS-based autoinjectors: evolution, market trends, and development challenges

Area of Science:

• Biopharmaceutical industry
• Drug delivery systems
• Medical device technology

Background:

• Self-injection is increasingly preferred for patient-administered therapies, especially for chronic diseases and immunotherapies.
• Prefilled syringe (PFS)-based autoinjectors are widely adopted due to convenience and patient acceptance.
• A gap exists in comprehensive reviews of disposable PFS-based autoinjectors.

Purpose of the Study:

• To systematically review disposable prefilled syringe-based autoinjectors.
• To analyze FDA-approved autoinjector products since 1980.
• To discuss technical challenges in autoinjector formulation development.

Main Methods:

• Systematic analysis of data from the U.S. Food and Drug Administration's official website.
• Inclusion of FDA-approved New Drug Applications (NDAs) and Biologics License Applications (BLAs) since 1980.
• Review of technical challenges in incorporating injectable formulations into spring-driven autoinjector systems.

Main Results:

• Identification of trends and key features of FDA-approved disposable PFS-based autoinjectors.
• Analysis of the evolution of autoinjector technology and regulatory approvals.
• Summary of common formulation challenges encountered in autoinjector development.

Conclusions:

• Disposable prefilled syringe autoinjectors are vital for modern biopharmaceutical therapies.
• Further research into technical challenges can lead to improved autoinjector design.
• Enhanced autoinjector platforms can improve patient experience and treatment adherence.